• Company
• Will Rivoceranib+Iressa really be a game changer ?
• by Jul 14, 2021 06:26pm

• Company
• Bavencio can be prescribed in general hospitals
• by Eo, Yun-Ho Jul 14, 2021 06:03am

• Company
• Will a new reimbursement model be introduced for Zolgensma?
• by Jul 14, 2021 06:03am

• Company
• CKD-701 demonstrated the validity in phase III trials
• by Chon, Seung-Hyun Jul 14, 2021 06:03am

• Company
• Omipalisib is 200 times more effective than Remdesivir
• by Kim, Jin-Gu Jul 13, 2021 11:09pm

• Company
• Dong-A ST has received the right of DA-4501 from AbbVie
• by An, Kyung-Jin Jul 13, 2021 11:08pm

• Policy
• Benefit plan of Keytruda & Tecentriq will be discussed
• by Moon, sung-ho Jul 13, 2021 11:08pm

• Company
• Venclexta combo in the spotlight as a new lymphoma Tx option
• by Jul 13, 2021 05:59am

• Company
• “Reimburse Vyndamax, the only hope for amyloidosis”
• by Eo, Yun-Ho Jul 13, 2021 05:59am

• InterView
• MSD "Will care for employees and new drug reimbursement"
• by Eo, Yun-Ho Jul 13, 2021 12:59am